Acs Fall 2025 Vvd 130037 Vvd1300370. Spring 2025 Osap Anthony Gibson Choose from thousands of presentations, network, attend courses and visit the expo. Program Area Deadline Program Chair(s) Program Admin(s) [AGFD] Division of Agricultural and Food Chemistry: 2025-03-31: Coralia Osorio Roa
Aknvas PreFall 2025 Collection [PHOTOS] from wwd.com
Berlin, Germany, San Diego, CA, USA, September 18, 2023 - Vividion Therapeutics, Inc A "covalent first" chemoproteomic approach to drug discovery has enabled the discovery of small molecule activators of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of the cytoprotective transcription factor nuclear factor-erythroid 2 p45-related factor 2…
Aknvas PreFall 2025 Collection [PHOTOS]
Join us at ACS Fall 2025 in Washington, DC or online, August 17-21 (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037 A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors.
Gmu 2025 Fall Calendar Spring Semester Avas Anderson. February 17, 2025 updated by: Vividion Therapeutics, Inc Program Area Deadline Program Chair(s) Program Admin(s) [AGFD] Division of Agricultural and Food Chemistry: 2025-03-31: Coralia Osorio Roa
Nccc Fall 2025 Calendar Zora Muriel. Choose from thousands of oral presentations covering every area of chemistry, attend the poster session and visit the expo hall to meet vendors and learn about new tools and processes Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors Major milestone for Vividion's chemoproteomics innovative technology platform First-in-class clinical candidate to target cancers with activation of KEAP1-NRF2 pathway BERLIN, Germany; SAN DIEGO, CA, USA I September 18, 2023 I Vividion.